At this year’s “Pharma Trends 2027” conference organised by Forum Institut, Matthias Hiller (CDU), member of the Health Committee of the German Bundestag, discussed the criteria of the planned location clause (Standortklausel) under § 130a SGB V. The plan is to exempt new medicinal products, from 1 January 2027, partially or fully from the additional manufacturer rebate of 8.5%, which is to be levied on top of the existing rebate of 7%.
The prerequisite is to be that at least 2% of the clinical trials are conducted in Germany. The amount of relief depends on further location criteria: a reduction of 2 percentage points is envisaged for collective bargaining coverage, 3 percentage points for certain research and development expenditure in Germany, and a further 3.5 percentage points for planned investment and production projects. A corresponding draft by the expert panel on the location clause is available.
Source: Results report of the expert panel “Standortklausel § 130a SGB V” (PDF, German).